GlassScriptPhysician profile
Robert B Watterson
NPI 1033187646
$1,455.51
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $568 · 2021: $188 · 2022: $127 · 2023: $18.22 · 2024: $21.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $261.49 | 2019 | |
| Novo Nordisk INC | $189.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $109.81 | 2019-2021 | |
| Janssen Biotech, INC. | $106.75 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.69 | 2019-2020 | |
| Lilly USA, LLC | $76.89 | 2019-2021 | |
| Therapeuticsmd, INC. | $71.94 | 2020-2021 | |
| Amgen INC. | $62.12 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.37 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $40.47 | 2020 | |
| Abbott Laboratories | $39.36 | 2023-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $37.55 | 2020-2021 | |
| Organon LLC | $33.69 | 2022 | |
| Lupin INC. | $33.30 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $24.74 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.09 | 2022 | |
| Exeltis, USA INC. | $16.53 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 | |
| Sanofi Pasteur INC. | $14.99 | 2019 | |
| Hologic INC | $12.99 | 2021 | |
| Amarin Pharma, INC. | $12.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Watterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.